A functional siRNA screen identifies genes modulating angiotensin II-mediated EGFR transactivation

Summary The angiotensin type 1 receptor (AT1R) transactivates the epidermal growth factor receptor (EGFR) to mediate cellular growth, however, the molecular mechanisms involved have not yet been resolved. To address this, we performed a functional siRNA screen of the human kinome in human mammary epithelial cells that demonstrate a robust AT1R–EGFR transactivation. We identified a suite of genes encoding proteins that both positively and negatively regulate AT1R–EGFR transactivation. Many candidates are components of EGFR signalling networks, whereas others, including TRIO, BMX and CHKA, have not been previously linked to EGFR transactivation. Individual knockdown of TRIO, BMX or CHKA attenuated tyrosine phosphorylation of the EGFR by angiotensin II stimulation, but this did not occur following direct stimulation of the EGFR with EGF, indicating that these proteins function between the activated AT1R and the EGFR. Further investigation of TRIO and CHKA revealed that their activity is likely to be required for AT1R–EGFR transactivation. CHKA also mediated EGFR transactivation in response to another G protein-coupled receptor (GPCR) ligand, thrombin, indicating a pervasive role for CHKA in GPCR–EGFR crosstalk. Our study reveals the power of unbiased, functional genomic screens to identify new signalling mediators important for tissue remodelling in cardiovascular disease and cancer.

[1]  David J. Forsthoefel,et al.  A genome-wide RNAi screen reveals a Trio-regulated Rho GTPase circuitry transducing mitogenic signals initiated by G protein-coupled receptors. , 2013, Molecular cell.

[2]  Evan Bolton,et al.  PubChem's BioAssay Database , 2011, Nucleic Acids Res..

[3]  R. Lefkowitz,et al.  β-Arrestin-mediated receptor trafficking and signal transduction. , 2011, Trends in pharmacological sciences.

[4]  T. Miyake,et al.  Functional interactions between Choline kinase α, epidermal growth factor receptor (EGFR), and c-Src in breast cancer cell proliferations , 2011, Oncogene.

[5]  H. Chan,et al.  Determination of the Exact Molecular Requirements for Type 1 Angiotensin Receptor Epidermal Growth Factor Receptor Transactivation and Cardiomyocyte Hypertrophy , 2011, Hypertension.

[6]  Zhiyong Guo,et al.  Tyrosine Kinase ETK/BMX Is Up-Regulated in Bladder Cancer and Predicts Poor Prognosis in Patients with Cystectomy , 2011, PloS one.

[7]  A. Yalçin,et al.  A Novel Small Molecule Antagonist of Choline Kinase-α That Simultaneously Suppresses MAPK and PI3K/AKT Signaling , 2011, Oncogene.

[8]  Damian Szklarczyk,et al.  The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored , 2010, Nucleic Acids Res..

[9]  R. Hannan,et al.  The renin–angiotensin system and cancer: old dog, new tricks , 2010, Nature Reviews Cancer.

[10]  M. Maoz,et al.  Etk/Bmx Regulates Proteinase-Activated-Receptor1 (PAR1) in Breast Cancer Invasion: Signaling Partners, Hierarchy and Physiological Significance , 2010, PloS one.

[11]  T. Unger,et al.  The angiotensin AT2 receptor in inflammation. , 2010, Drug news & perspectives.

[12]  E. Schiffrin T lymphocytes: a role in hypertension? , 2010, Current opinion in nephrology and hypertension.

[13]  R. Torres,et al.  The Rho exchange factor Arhgef1 mediates the effects of angiotensin II on vascular tone and blood pressure , 2010, Nature Medicine.

[14]  A. Lane,et al.  Selective inhibition of choline kinase simultaneously attenuates MAPK and PI3K/AKT signaling , 2010, Oncogene.

[15]  Y. Obara,et al.  Thromboxane A2 receptor-mediated epidermal growth factor receptor transactivation: involvement of PKC-delta and PKC-epsilon in the shedding of epidermal growth factor receptor ligands. , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[16]  Aideen Long,et al.  Statistical methods for analysis of high-throughput RNA interference screens , 2009, Nature Methods.

[17]  C. Cordon-Cardo,et al.  A critical role for choline kinase-α in the aggressiveness of bladder carcinomas , 2009, Oncogene.

[18]  Alnawaz Rehemtulla,et al.  AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist , 2009, Proceedings of the National Academy of Sciences.

[19]  T. Park,et al.  A role for the renin-angiotensin system in hematopoiesis , 2009, Haematologica.

[20]  T. Walther,et al.  Angiotensin-(1–7) stimulates hematopoietic progenitor cells in vitro and in vivo , 2009, Haematologica.

[21]  M. Iwai,et al.  Role of renin–angiotensin system in adipose tissue dysfunction , 2009, Hypertension Research.

[22]  S. Love,et al.  Angiotensin-converting enzyme levels and activity in Alzheimer's disease: differences in brain and CSF ACE and association with ACE1 genotypes. , 2009, American journal of translational research.

[23]  Alexei Degterev,et al.  Identification of a Molecular Signaling Network that Regulates a Cellular Necrotic Cell Death Pathway , 2008, Cell.

[24]  T. Vondriska,et al.  Loss of Bmx Nonreceptor Tyrosine Kinase Prevents Pressure Overload–Induced Cardiac Hypertrophy , 2008, Circulation research.

[25]  Elias T. Zambidis,et al.  Expression of angiotensin-converting enzyme (CD143) identifies and regulates primitive hemangioblasts derived from human pluripotent stem cells. , 2008, Blood.

[26]  Anastasia Khvorova,et al.  Identification of genes that regulate epithelial cell migration using an siRNA screening approach , 2008, Nature Cell Biology.

[27]  B. Cuevas,et al.  Persistent transactivation of EGFR and ErbB2/HER2 by protease-activated receptor-1 promotes breast carcinoma cell invasion , 2008, Oncogene.

[28]  S. Eguchi,et al.  Central role of Gq in the hypertrophic signal transduction of angiotensin II in vascular smooth muscle cells. , 2008, Endocrinology.

[29]  A. Daugherty,et al.  The role of the renin-angiotensin system in aortic aneurysmal diseases , 2008, Current hypertension reports.

[30]  A. Hyman,et al.  Genome-scale RNAi profiling of cell division in human tissue culture cells , 2007, Nature Cell Biology.

[31]  R. Kaur,et al.  Activation of Nonreceptor Tyrosine Kinase Bmx/Etk Mediated by Phosphoinositide 3-Kinase, Epidermal Growth Factor Receptor, and ErbB3 in Prostate Cancer Cells* , 2007, Journal of Biological Chemistry.

[32]  E. Jorgensen,et al.  Trio’s Rho-specific GEF domain is the missing Gαq effector in C. elegans , 2007 .

[33]  J. Sondek,et al.  Gαq Directly Activates p63RhoGEF and Trio via a Conserved Extension of the Dbl Homology-associated Pleckstrin Homology Domain* , 2007, Journal of Biological Chemistry.

[34]  S. Young,et al.  Early Embryonic Lethality Caused by Disruption of the Gene for Choline Kinase α, the First Enzyme in Phosphatidylcholine Biosynthesis* , 2007, Journal of Biological Chemistry.

[35]  Yusu Gu,et al.  erbB2 is required for G protein-coupled receptor signaling in the heart , 2006, Proceedings of the National Academy of Sciences.

[36]  P. Dempsey,et al.  ADAM17 Mediates Epidermal Growth Factor Receptor Transactivation and Vascular Smooth Muscle Cell Hypertrophy Induced by Angiotensin II , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[37]  Michael C. Ostrowski,et al.  Tyrosine kinase Etk/BMX is up-regulated in human prostate cancer and its overexpression induces prostate intraepithelial neoplasia in mouse. , 2006, Cancer research.

[38]  G. Vinson,et al.  Localisation of renin-angiotensin system (RAS) components in breast , 2006, British Journal of Cancer.

[39]  L. Hunyady,et al.  Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II. , 2006, Molecular endocrinology.

[40]  B. H. Shah,et al.  TACE-dependent EGF receptor activation in angiotensin-II-induced kidney disease. , 2006, Trends in pharmacological sciences.

[41]  H. Chan,et al.  Effect of Dominant-Negative Epidermal Growth Factor Receptors on Cardiomyocyte Hypertrophy , 2006, Journal of receptor and signal transduction research.

[42]  M. Crouch,et al.  GPCR Screening via ERK 1/2: A Novel Platform for Screening G Protein–Coupled Receptors , 2005, Journal of biomolecular screening.

[43]  M. Mifune,et al.  G Protein Coupling and Second Messenger Generation Are Indispensable for Metalloprotease-dependent, Heparin-binding Epidermal Growth Factor Shedding through Angiotensin II Type-1 Receptor* , 2005, Journal of Biological Chemistry.

[44]  T. Wieland,et al.  The Guanine Nucleotide Exchange Factor p63RhoGEF, a Specific Link between Gq/11-coupled Receptor Signaling and RhoA* , 2005, Journal of Biological Chemistry.

[45]  D. Megías,et al.  Choline Kinase Activation Is a Critical Requirement for the Proliferation of Primary Human Mammary Epithelial Cells and Breast Tumor Progression , 2004, Cancer Research.

[46]  Yi Zheng,et al.  Rational design and characterization of a Rac GTPase-specific small molecule inhibitor. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[47]  C. Aoyama,et al.  Structure and function of choline kinase isoforms in mammalian cells. , 2004, Progress in lipid research.

[48]  Darrell R. Abernethy,et al.  International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels , 2003, Pharmacological Reviews.

[49]  A. Muscella,et al.  Angiotensin II activates extracellular signal regulated kinases via protein kinase C and epidermal growth factor receptor in breast cancer cells , 2003, Journal of cellular physiology.

[50]  J. Sadoshima,et al.  Phosphorylation of Tyrosine 319 of the Angiotensin II Type 1 Receptor Mediates Angiotensin II-induced Trans-activation of the Epidermal Growth Factor Receptor* , 2003, The Journal of Biological Chemistry.

[51]  R. Hannan,et al.  Adenoviral-Directed Expression of the Type 1A Angiotensin Receptor Promotes Cardiomyocyte Hypertrophy via Transactivation of the Epidermal Growth Factor Receptor , 2002, Circulation research.

[52]  B. H. Shah,et al.  Calcium-independent activation of extracellularly regulated kinases 1 and 2 by angiotensin II in hepatic C9 cells: roles of protein kinase Cdelta, Src/proline-rich tyrosine kinase 2, and epidermal growth receptor trans-activation. , 2002, Molecular Pharmacology.

[53]  E. Schiffrin,et al.  Increased Angiotensin II-Mediated Src Signaling via Epidermal Growth Factor Receptor Transactivation Is Associated With Decreased C-Terminal Src Kinase Activity in Vascular Smooth Muscle Cells From Spontaneously Hypertensive Rats , 2002, Hypertension.

[54]  Y. Mori,et al.  Angiotensin II signaling and HB-EGF shedding via metalloproteinase in glomerular mesangial cells. , 2001, Kidney International.

[55]  K. Chien,et al.  Absence of pressure overload induced myocardial hypertrophy after conditional inactivation of Gαq/Gα11 in cardiomyocytes , 2001, Nature Medicine.

[56]  H. Qian,et al.  Association of beta-Arrestin 1 with the type 1A angiotensin II receptor involves phosphorylation of the receptor carboxyl terminus and correlates with receptor internalization. , 2001, Molecular endocrinology.

[57]  L. Vakaet,et al.  Growth stimulatory angiotensin II type-1 receptor is upregulated in breast hyperplasia and in situ carcinoma but not in invasive carcinoma , 2001, Histochemistry and Cell Biology.

[58]  J. Schlessinger,et al.  Src and Pyk2 Mediate G-protein-coupled Receptor Activation of Epidermal Growth Factor Receptor (EGFR) but Are Not Required for Coupling to the Mitogen-activated Protein (MAP) Kinase Signaling Cascade* , 2001, The Journal of Biological Chemistry.

[59]  D. Weiss,et al.  Angiotensin II and atherosclerosis. , 2001, The American journal of cardiology.

[60]  S Eguchi,et al.  Activation of MAPKs by Angiotensin II in Vascular Smooth Muscle Cells , 2001, The Journal of Biological Chemistry.

[61]  K. Catt,et al.  International union of pharmacology. XXIII. The angiotensin II receptors. , 2000, Pharmacological reviews.

[62]  V. Karoor,et al.  Phosphorylation of the angiotensin II (AT1A) receptor carboxyl terminus: a role in receptor endocytosis. , 1998, Molecular endocrinology.

[63]  H. Kawakatsu,et al.  Calcium-dependent Epidermal Growth Factor Receptor Transactivation Mediates the Angiotensin II-induced Mitogen-activated Protein Kinase Activation in Vascular Smooth Muscle Cells* , 1998, The Journal of Biological Chemistry.

[64]  Xin-Yun Huang,et al.  Direct stimulation of Bruton's tyrosine kinase by Gq-protein α-subunit , 1997, Nature.

[65]  K. Alitalo,et al.  Bmx tyrosine kinase is specifically expressed in the endocardium and the endothelium of large arteries. , 1997, Circulation.

[66]  A. Debant,et al.  The multidomain protein Trio binds the LAR transmembrane tyrosine phosphatase, contains a protein kinase domain, and has separate rac-specific and rho-specific guanine nucleotide exchange factor domains. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[67]  A. Ullrich,et al.  Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors , 1996, Nature.

[68]  Y. Wan,et al.  Activation of Tsk and Btk tyrosine kinases by G protein beta gamma subunits. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[69]  C. Larsson,et al.  BMX, a novel nonreceptor tyrosine kinase gene of the BTK/ITK/TEC/TXK family located in chromosome Xp22.2. , 1994, Oncogene.

[70]  M. Simon,et al.  Binding of beta gamma subunits of heterotrimeric G proteins to the PH domain of Bruton tyrosine kinase. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[71]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[72]  W. Elliott Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis , 2011 .

[73]  F. Vesuna,et al.  Hypoxia regulates choline kinase expression through hypoxia-inducible factor-1 alpha signaling in a human prostate cancer model. , 2008, Cancer research.

[74]  K. Griendling,et al.  Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. , 2007, American journal of physiology. Cell physiology.

[75]  E. Jorgensen,et al.  Trio's Rho-specific GEF domain is the missing Galpha q effector in C. elegans. , 2007, Genes & development.

[76]  Michael D. Abràmoff,et al.  Image processing with ImageJ , 2004 .

[77]  Lijun Liu,et al.  HUMAN BREAST CANCER CELLS , 2004 .

[78]  Hiroshi Asanuma,et al.  Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: Metalloproteinase inhibitors as a new therapy , 2002, Nature Medicine.

[79]  W. Hahn,et al.  Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. , 2001, Genes & development.

[80]  K. Chien,et al.  Absence of pressure overload induced myocardial hypertrophy after conditional inactivation of Galphaq/Galpha11 in cardiomyocytes. , 2001, Nature medicine.

[81]  S Rozen,et al.  Primer3 on the WWW for general users and for biologist programmers. , 2000, Methods in molecular biology.

[82]  Y. Hirata,et al.  Involvement of PYK2 in angiotensin II signaling of vascular smooth muscle cells. , 1999, Hypertension.

[83]  R. Ardaillou Angiotensin II receptors. , 1999, Journal of the American Society of Nephrology : JASN.

[84]  J. Massagué TGF-beta signal transduction. , 1998, Annual review of biochemistry.

[85]  T. Kozasa,et al.  Direct stimulation of Bruton's tyrosine kinase by G(q)-protein alpha-subunit. , 1997, Nature.

[86]  D. Pw [The renin-angiotensin system]. , 1997 .